4//SEC Filing
Pontifax Late Stage GP Ltd. 4
Accession 0001209191-20-059404
CIK 0001664710other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 4:38 PM ET
Size
21.2 KB
Accession
0001209191-20-059404
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2020-11-17$50.00/sh+12,966$648,300→ 1,122,768 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+26,634$1,331,700→ 2,288,151 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+14,400$720,000→ 1,228,326 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+6,000$300,000→ 155,262 total(indirect: See footnote)
Pontifax (Israel) IV, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2020-11-17$50.00/sh+12,966$648,300→ 1,122,768 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+14,400$720,000→ 1,228,326 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+26,634$1,331,700→ 2,288,151 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+6,000$300,000→ 155,262 total(indirect: See footnote)
Pontifax (Cayman) IV L.P.
10% Owner
Transactions
- Purchase
Common Stock
2020-11-17$50.00/sh+26,634$1,331,700→ 2,288,151 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+6,000$300,000→ 155,262 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+12,966$648,300→ 1,122,768 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+14,400$720,000→ 1,228,326 total(indirect: See footnote)
Pontifax (China) IV L.P.
10% Owner
Transactions
- Purchase
Common Stock
2020-11-17$50.00/sh+6,000$300,000→ 155,262 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+26,634$1,331,700→ 2,288,151 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+14,400$720,000→ 1,228,326 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+12,966$648,300→ 1,122,768 total(indirect: See footnote)
Pontifax Late Stage Fund L.P.
10% Owner
Transactions
- Purchase
Common Stock
2020-11-17$50.00/sh+26,634$1,331,700→ 2,288,151 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+12,966$648,300→ 1,122,768 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+14,400$720,000→ 1,228,326 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+6,000$300,000→ 155,262 total(indirect: See footnote)
Pontifax Late Stage GP Ltd.
10% Owner
Transactions
- Purchase
Common Stock
2020-11-17$50.00/sh+26,634$1,331,700→ 2,288,151 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+12,966$648,300→ 1,122,768 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+14,400$720,000→ 1,228,326 total(indirect: See footnote) - Purchase
Common Stock
2020-11-17$50.00/sh+6,000$300,000→ 155,262 total(indirect: See footnote)
Footnotes (5)
- [F1]The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F2]The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F3]The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F4]The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds.
- [F5]Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001793770
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 4:38 PM ET
- Size
- 21.2 KB